A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia
James B. Bussel(Cornell University), Joe McIntosh(Eisai (United States)), Louis M. Aledort(Icahn School of Medicine at Mount Sinai), Kelly Pendergrass(Breast Center), Craig M. Kessler(Georgetown University), Adam Cuker(University of Pennsylvania), Shande Tang(Eisai (United States)), David J. Kuter(Harvard University)
Cited by 162
Related Papers
American Society of Hematology 2020 Guidelines for Management of Venous Thromboembolism: Treatment of Deep Vein Thrombosis and Pulmonary Embolism
|Blood Advances|2020|1.4k
Updated international consensus report on the investigation and management of primary immune thrombocytopenia
|Blood Advances|2019|1.1k
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
|New England Journal of Medicine|2003|809